97 / 490
SUNDAY 1 MAY 2016
95
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
> Risk assessment of solid secondary malignancies in childhood Hodgkin
Lymphoma after radiotherapy
G. Zanella, M. Mascarin (Italy), A. Drigo, A. Pusiol, E.C. Fuga, F.M.
Giugliano, A. Rosolen, M.G. Trovò
PV-0230
Symposium
QA IN CLINICAL TRIALS: PROCESSES, IMPACT AND FUTURE
PERSPECTIVES
10:45 - 11:45 | ROOM 2
Clinical trials traditionally form the basis on which evidence-based guidelines are made. Therefore the
quality of the data should be closely monitored. Quality Assurance requirements for every step of the
process of trial preparation, conduct and analysis will be presented and illustrated using several practical
examples on how protocol deviations led to jeopardising significant investments in terms of manpower
and money. Recent developments towards intensive international collaboration across different trial
organisations will contribute to the streamlining of this process. Ultimately, effective QA management in
clinical trials will be of benefit of all patients whether they participate or not in clinical trials.
Chair: P. Poortmans (The Netherlands)
Co-chair: N. Romeo (Italy)
10:45 > How effective is current clinical trial QA?
Speaker: E. Miles (UK)
SP-0231
11:05 > How does QA impact on clinical outcomes?
Speaker: D.C. Weber (Switzerland)
SP-0232
11:25 > What will we need for future RTQA in clinical trials?
Speaker: C. Hurkmans (The Netherlands)
SP-0233
Proffered Papers
RADIOBIOLOGY 3: NOVEL TARGETING APPROACHES IN COMBINATION
WITH RADIATION
10:45 - 11:45 | LONDRA
Chair: G. Higgins (UK)
Chair: M. Verheij (The Netherlands)
10:45 > Radiotherapy and L19-IL2: perfect match for an abscopal effect with
long-lasting memory
N.H. Rekers (The Netherlands), A. Yaromina, N.G. Lieuwes, R. Biemans,
W.T.V. Germeraad, D. Neri, L. Dubois, P. Lambin
OC-0234
10:55 > Enhancing stereotactic radiation schedules using the vascular disrupting
agent OXi4503
M.R. Horsman (Denmark), T.R. Wittenborn
OC-0235